Evaluation of the clinical effectiveness of various anti-relapse therapy regimens in children with pyelonephritis


Cite item

Full Text

Abstract

Relevance. Currently, pyelonephritis (PN) remains one of the most common bacterial infections in children. Treatment of chronic PN (CP) should be based on the principles of staging, continuity and continuity. Purpose. Evaluation of the advisability of prescribing anti-relapse therapy, its tolerability and the effectiveness of various regimens to prevent relapse in children with acute and CP. Materials and methods. The study involved 167 children from 2 to 12 years old, including 139 (83.2%) girls and 28 boys (16.8%). Children were divided into the following groups: 1A (n=32) with the onset of acute PN, received cephalosporins (CS) of the third generation for 10-14 days; 1B (n=35) - with the onset of acute PN, received third-generation CS for 10-14 days, then for 1 month - a combination of standardized extracts of BNO 1040; group 2A (n=32) with recurrent CP received third generation CS for 10-14 days, then furazidine for 14 days; group 2B (n=34) with recurrent CP received third generation CS for 10-14 days, then furazidin for 14 days, then a combination of standardized extracts of BNO 1040 for 1 month; group 2B (n=34) with recurrent CP received third-generation CS for 10-14 days, then a combination of standardized extracts of BNO 1040 for 3 months. Results. During anti-relapse therapy, all patients in group 1B showed no recurrence of the disease in the first 6 months after the end of antibiotic therapy, as well as a tendency to increase the duration of the remission period when compared with group 1A. Among patients with CP, the least effective treatment regimen was used for group 2A; it was statistically significantly (p<0.05) inferior in anti-relapse effect to groups 2B and 2C. No significant differences were found between group 2B and group 2C. Conclusion. The use of anti-relapse therapy in children with acute PN reduces the likelihood of relapse in the first 2 years from the onset of the disease. Among patients with CP, the optimal results for an increase in the remission period were obtained with a combination therapy furazidine + a combination of standardized extracts BNO 1040 or long-term herbal therapy with a combination of standardized extracts BNO 1040.

Full Text

Restricted Access

About the authors

Alina V. Eremeeva

Sechenov First Moscow State Medical University (Sechenov University)

Email: alinaeremeeva@yandex.ru
Moscow, Russia

References

  1. Ma JF, Diariki Shortliffe LM. Urinary tract infection in children: etiology and epidemiology Urol Clin North Am 2004; 31 (3): 517-26, ix-x. doi: 10.1016/j.ucl.2004.04.016
  2. Leung AKC, Wong AHC, Leung AAM, Hon KL. Urinary Tract Infection in Children. Recent Pat Inflamm Allergy Drug Discov 2019; 13 (1): 2-18. doi: 10.2174/1872213X13666181228154940
  3. Eremenko R, Barmatz S, Lumelsky N et al. Urinary Tract Infection in Outpatient Children and Adolescents: Risk Analysis of Antimicrobial Resistance. Isr Med Assoc J 2020; 22 (4): 236-40.
  4. Инфекция мочевой системы у детей. Руководство для врачей. Под ред. В.ВДлина, И.М.Османова, О.Л.Чугуновой (сост. С.Л.Морозов). 2-е изд., доп. М.: Оверлей, 2017.
  5. Вялкова А.А., Гриценко В.А. Инфекция мочевой системы у детей: современные аспекты этиологической диагностики и лечения. Рос. вестн. перинатологии и педиатрии. 2017; 62 (1): 99-108.
  6. Падейская Е.Н. Фурамаг в ряду антимикробных препаратов, производных 5-нитрофурана: значение для клинической практики. Инфекции и антимикробная терапия. 2004; 6 (1): 24-31.
  7. Chang SL, Shortliffe LD. Pediatric urinary tract infections. Pediatr Clin North Am 2006; 53 (3): 379-400.
  8. Balighian E, Burke M. Urinary Tract Infections in Children. Pediatr Rev 2018; 39 (1): 3-12. doi: 10.1542/pir.2017-0007
  9. Вдовиченко В.П., Бронская Г.М., Коршак ТА и др. Нитрофураны в фармакотерапии инфекций мочевыводящих путей. Мед. новости. 2012; 3: 38-41.
  10. Dlin VV, Abramov-Sommariva D, Zakharova IN et al. A non-interventional, prospective, multicenter study for evaluation of the use of the herbal medicinal product Canep-hron® N in the pediatric outpatient population in Russia. Clin Phytosci 2018; 4: 31.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies